# Lisata Therapeutics Inc. (LSTA)

Source: https://www.quantisnow.com/company/LSTA
Generated: 2026-11-14T10:26:22.534Z

- Ticker: LSTA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000320017

## Latest LSTA news and filings

- 2026-11-13 21:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lisata-therapeutics-inc-6790559)
- 2026-11-12 22:16 UTC [SEC Form S-3] [SEC Form S-3 filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-lisata-therapeutics-inc-6788807)
- 2026-11-12 22:13 UTC [SEC Form S-8] [SEC Form S-8 filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-lisata-therapeutics-inc-6788793)
- 2026-11-12 11:07 UTC [SEC Form 8-K] [Amendment: Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-lisata-therapeutics-inc-filed-sec-form-8-k-financial-statements-6785783)
- 2026-11-09 22:19 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-lisata-therapeutics-inc-6782072)
- 2026-11-09 22:15 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-leadership-update-submission-6782055)
- 2026-11-09 14:00 UTC [Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine](https://www.quantisnow.com/insight/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-mar001-reduces-6780588)
- 2026-11-05 13:30 UTC [Conference Announcement] [Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences](https://www.quantisnow.com/insight/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-to-participate-in-6774988)
- 2026-10-19 10:38 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-lisata-therapeutics-inc-6749838)
- 2026-10-16 00:44 UTC [SEC Form 3] [SEC Form 3 filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-lisata-therapeutics-inc-6748508)
- 2026-10-14 20:25 UTC [SEC Form 8-K] [SEC Form 8-K filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-lisata-therapeutics-inc-6746702)
- 2026-10-14 20:05 UTC [Leadership Update] [Lisata Therapeutics Appoints Jeff Farrow to Board of Directors](https://www.quantisnow.com/insight/lisata-therapeutics-appoints-jeff-farrow-to-board-of-directors-6746497)
- 2026-10-08 12:00 UTC [Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors](https://www.quantisnow.com/insight/lisata-therapeutics-announces-new-method-of-use-patent-granted-for-6741131)
- 2026-10-07 21:17 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-lisata-therapeutics-inc-6740616)
- 2026-10-05 12:00 UTC [Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly](https://www.quantisnow.com/insight/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-6735962)
- 2026-10-02 20:23 UTC [SEC Form D] [SEC Form D filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-lisata-therapeutics-inc-6734707)
- 2026-09-29 01:30 UTC [SEC Form 3] [New insider Love Ted W claimed ownership of 19,260 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-love-ted-w-claimed-ownership-of-19260-shares-6728172)
- 2026-09-29 01:29 UTC [SEC Form 3] [New insider Lehrer-Graiwer Joshua claimed ownership of 27,808 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-lehrer-graiwer-joshua-claimed-ownership-of-27808-shares-sec-6728171)
- 2026-09-24 12:00 UTC [Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026](https://www.quantisnow.com/insight/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-upcoming-late-breaking-6724829)
- 2026-09-17 13:27 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6718717)
- 2026-09-17 13:26 UTC [Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement](https://www.quantisnow.com/insight/lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-6718715)
- 2026-08-06 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lisata-therapeutics-inc-6668676)
- 2026-08-04 11:00 UTC [Lisata Therapeutics Provides Update Following Termination of Merger Agreement](https://www.quantisnow.com/insight/lisata-therapeutics-provides-update-following-termination-of-merger-agreement-6660906)
- 2026-08-04 10:01 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-costs-associated-with-6660736)
- 2026-07-24 16:15 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-termination-of-a-6648127)
- 2026-07-21 10:00 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-lisata-therapeutics-inc-6643038)
- 2026-07-17 11:01 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6640479)
- 2026-07-17 10:56 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-lisata-therapeutics-inc-6640461)
- 2026-07-13 10:02 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-lisata-therapeutics-inc-6634632)
- 2026-07-02 20:06 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-lisata-therapeutics-inc-6625172)
- 2026-06-10 12:38 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-lisata-therapeutics-inc-6596555)
- 2026-06-10 12:00 UTC [Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.](https://www.quantisnow.com/insight/lisata-therapeutics-announces-commencement-of-tender-offer-by-kuva-labs-6596405)
- 2026-06-09 11:31 UTC [SEC Form SC14D9C filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-lisata-therapeutics-inc-6594540)
- 2026-06-09 11:30 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6594529)
- 2026-06-01 10:09 UTC [SEC Form SC14D9C filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-lisata-therapeutics-inc-6580407)
- 2026-06-01 10:03 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-other-events-6580390)
- 2026-05-29 20:59 UTC [SEC Form SC14D9C filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-lisata-therapeutics-inc-6579737)
- 2026-05-29 20:50 UTC [SEC Form 8-K] [Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/lisata-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6579673)
- 2026-05-11 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lisata-therapeutics-inc-6544687)
- 2026-05-04 10:04 UTC [SEC Form SC14D9C filed by Lisata Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-lisata-therapeutics-inc-6527819)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LSTA
- Earnings history: https://www.quantisnow.com/earnings/LSTA
- Dividend history: https://www.quantisnow.com/dividends/LSTA
- Insider transactions: https://www.quantisnow.com/insiders/LSTA
- Options chain: https://www.quantisnow.com/options/LSTA
- SEC 8-K filings only: https://www.quantisnow.com/company/LSTA/8-k
- RSS and alerts for LSTA: https://www.quantisnow.com/docs/rss-feeds.md